Schonfeld Strategic Advisors’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Schonfeld Strategic Advisors’s Portfolio NGM Stock Details NGM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-11,000	Closed	-$44.9K	–	2621
2023 Q1	$44.9K	Sell	11,000 -19,900	-64%	-$92K	﹤0.01%	1781
2022 Q4	$155K	Sell	30,900 -41,482	-57%	-$260K	﹤0.01%	2065
2022 Q3	$946K	Buy	+72,382	New	+$1.1M	0.01%	1307
2022 Q1	–	Sell	-13,700	Closed	-$243K	–	3014
2021 Q4	$243K	Buy	+13,700	New	+$263K	﹤0.01%	1637
2021 Q3	–	Sell	-30,253	Closed	-$597K	–	2558
2021 Q2	$597K	Buy	+30,253	New	+$708K	0.01%	1111
2019 Q3	–	Sell	-55,000	Closed	-$805K	–	1295
2019 Q2	$805K	Buy	+55,000	New	+$805K	0.03%	505

Other funds holding NGM

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Schonfeld Strategic Advisors's NGM Position: Q2 2023 in Review

Schonfeld Strategic Advisors sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2023, closing a stake of 11,000 shares — an estimated $44.9K sold.

Schonfeld Strategic Advisors first reported a position in NGM in Q2 2019 and held it in 6 quarters. The position peaked at $946K in Q3 2022. 106 funds tracked by Wall St. Rank hold NGM as of Q2 2023.

Schonfeld Strategic Advisors reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Schonfeld Strategic Advisors sold 11,000 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2023, an estimated $44.9K.
Schonfeld Strategic Advisors first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 6 quarters.
Schonfeld Strategic Advisors's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $946K in Q3 2022.
106 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2023.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.